Podcasts about Ovarian cancer

When faced with a Stage IV terminal cancer diagnosis at age 37, how do you keep living, surfing big waves, and raising a child?In this powerful episode, author and big-wave surfer Melanie Ezell joins Leah to share her unfiltered story of surviving Stage IV ovarian cancer, navigating recurrences, and finding profound joy despite an incurable diagnosis.Melanie, author of the memoir Inherited: A Life Without a Cure and writer behind the popular Substack An Incurable Life, opens up about using big-wave surfing to mirror her mental health, taking ownership of her healing, and building a life fully lived alongside mortality.In this episode:Surfing as a Mirror: Melanie's journey from Michigan to riding big waves in Hawaii and Mexico—and how the ocean reflects her inner emotional state.The Diagnosis: Her BRCA1 genetic mutation background, subtle ovarian cancer symptoms, and receiving a Stage IV diagnosis in 2022.Integrative & Alternative Cancer Care: Navigating ketogenic and Gerson diets, fasting, supplements, Dr. Joe Dispenza meditation, and plant medicine (Ayahuasca and Psilocybin) in search of the “root” cause of her cancer.Addressing Emotional Roots: How tackling codependency, resentment, setting firm boundaries, and writing her memoir became crucial parts of her healing journey.(Note: Brief mention of past eating disorders).Subscribe to Melanie on Substack: https://substack.com/@melanieezellVisit her website http://www.melanieezell.comFollow her on Instagram @yogasurfmeland Facebook https://www.facebook.com/melanie.malskiBuy her book, Inherited: A Life Without a CureLeave a message with your thoughts about the episode!Support the showBecome a member of The Cancer Pod Community! Support the podcast and gain access to exclusive content and more! Join today on Buy Me a Coffee or Patreon.Check out thecancerpod.com! Looking for more information? The website has blogs, merch, and all of the episodes listed by season and category. Shop the Bookshop! The shelves at Bookshop feature books by authors who have been on the show and other fav books.Buy The Cancer Pod merch! Whether it's a cozy hoody or a handy water bottle, we have something for everybody.Have a comment or suggestion? Email info (at) thecancerpod (dot) com Follow @TheCancerPod on social media:InstagramBlueskyFacebookLinkedInYouTube

Featuring perspectives from Dr Shannon N Westin and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) Ovarian Cancer (2:22) Endometrial Cancer (37:48) CME information and select publications

Get your FREE copy of "Your AZ Guide to Staying Cancer Free" here: https://www.cancerfreedomprogram.com/azcancerfree?utm_source=youtube&utm_content=ovarian_cancer_survivors Most ovarian cancer survivors leave treatment with a scan schedule and nothing else. Nobody explains what actually lowers recurrence risk in between. If you just finished treatment or you are years out, you know how quiet it gets once the appointments slow down. That quiet is where most women are left guessing. This isn't about hype. It's about simple changes you can start today. So let me show you how it's done. Join the Cancer Freedom Program Apply HERE: https://www.cancerfreedomprogram.com/?utm_source=youtube&utm_content=ovarian_cancer_survivors #cancerfighter #cancersurvivor #breastcancer #breastcancersurvivors #cancerrecovery #cancernutrition #mastectomy #tamoxifen #anastrozole #letrozole #exemestane PS: Whenever you're ready, here are the 2 best ways I can help you. Get your FREE copy of "Your AZ Guide to Staying Cancer Free" here: https://www.cancerfreedomprogram.com/azcancerfree?utm_source=youtube&utm_content=ovarian_cancer_survivors Join the Cancer Freedom Program Apply HERE: https://www.cancerfreedomprogram.com/?utm_source=youtube&utm_content=ovarian_cancer_survivors Let's Connect: Website: https://www.cancerfreedomprogram.com/?utm_source=youtube&utm_content=ovarian_cancer_survivors  

Ovarian Cancer Research Foundation chief executive Robin Penty joined Jimmy Bartel and Mark Allen to discuss the 'Frocktober' fundraising initiative.See omnystudio.com/listener for privacy information.

Featuring a slide presentation and related discussion from Professor Nicoletta Colombo, including the following topics: Rationale for targeting the glucocorticoid receptor; relacorilant mechanism of action (0:00) Key efficacy and safety findings from a Phase II study of relacorilant/nab paclitaxel for platinum-ineligible ovarian cancer (3:09) Key findings from the Phase III ROSELLA study (7:06) Case: A woman in her early 50s with FIGO Stage IVB platinum-ineligible high-grade serous carcinoma of the fallopian tube enrolls in the Phase III ROSELLA study (15:02) Case: A woman in her late 40s with FIGO Stage IIIB platinum-ineligible high-grade serous ovarian carcinoma enrolls in the Phase II BELLA trial (23:42) CME information and select publications

Featuring an interview with Professor Nicoletta Colombo, including the following topics: Mechanistic effects and rationale underlying the use of relacorilant/nab paclitaxel (0:00) Rationale underlying the study design of the Phase II BELLA trial and avenues for future exploration (8:31) Definition of platinum ineligibility; importance of platinum-containing chemotherapy for patients with ovarian cancer (14:02) Findings from a Phase II trial and the subsequent confirmatory Phase III ROSELLA study (20:25) Phase III ROSELLA study: Subgroup analyses, patient-reported outcomes, insights into overall survival data and common adverse events (29:43) Considerations for therapeutic selection and sequencing of novel therapies; ongoing and future investigations (38:46) CME information and select publications

September 29, 2026 ~ Marie Osborne, WJR's Director of Community Affairs and News. September is Ovarian Cancer awareness month, Corewell has some revolutionary treatments to fight Ovarian Cancer. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

September 29, 2026 ~ September is Ovarian Cancer Awareness Month. Marie Osborne joins Kevin to share more on the latest research being done for Ovarian Cancer. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Could ovarian cancer prevention extend beyond gynecologic surgery?In this episode, PhD student Katherine Huerne joins us to discuss her research on expanding opportunistic salpingectomy into general surgery in British Columbia. She explores the feasibility, ethical considerations, and clinical changes involved in bringing this promising prevention strategy into a new surgical setting.Tune in to learn how Katherine's work could help shape the future of ovarian cancer prevention.For more information on the Gynecologic Cancer Initiative, please visit https://gynecancerinitiative.ca/ or email us at info@gynecancerinitiative.ca  Where to learn more about us:  Twitter – @GCI_Cluster Instagram – @gynecancerinitiative Facebook – facebook.com/gynecancerinitiativeTikTok – @gci_gosh

JAMA Medical News Director Jennifer Abbasi and Associate Managing Editor Kate Schweitzer discuss "Remove the Fallopian Tubes If the Opportunity Arises, ACOG Says in New Ovarian Cancer Prevention Guidance." Related Content: Remove the Fallopian Tubes If the Opportunity Arises, ACOG Says in New Ovarian Cancer Prevention Guidance

What happens when you feel completely healthy — only to discover that cancer has been quietly spreading throughout your body? This episode marks the first of a new series on the HEAL with Kelly Podcast: HEALing Stories, where we're creating more space to share real people, real healing journeys, and powerful stories of hope and resilience. In this powerful HEALing Story, Stacy Solodkin shares her extraordinary journey from an unexpected Stage 3C ovarian cancer diagnosis to being eight years out with no evidence of disease. Stacy opens up about the subtle symptom that sent her to the emergency room, the moment she was told cancer was “everywhere,” and why trusting her intuition and refusing to be sent home may have saved her life. She shares the importance of advocating for yourself, seeking second opinions, and finding a medical team that truly feels aligned with you. Stacy also takes us inside the whole-person approach she embraced alongside conventional cancer treatment — from nutrition and acupuncture to meditation and other supportive therapies — and how the HEAL documentary helped expand her understanding of the role she could play in her own healing. But Stacy's story is about much more than cancer. Facing her mortality completely transformed the way she lives. She learned to stop waiting for “someday,” release fear and difficult emotions, receive support, and ask herself one powerful question: How will I feel about this decision on my last day? Her story is a moving reminder to listen to your body, advocate for yourself, and not wait for a diagnosis to start living the life you truly want. LINKS Stacy Solodkin on Instagram @stacysolodkin Key Moments You'll Love ✨ :

  Summary Join Jayla and Shaye as they chat about life, health, and personal growth, exploring topics like trapped emotions, healthy aging, and the power of positive affirmations. This episode offers practical insights and a light-hearted look at how to live a happier, healthier life.   Keywords:  personal growth, health, trapped emotions, positive affirmations, aging, wellness, mental health, lifestyle, self-care, motivation   Key Topics Trapped emotions and their impact on health Longevity secrets from Japan and their lifestyle habits Preventative health measures like fallopian tube removal The concept of mind movies for manifestation The role of community and social connections in aging well Sound Bites "Removing fallopian tubes can reduce ovarian cancer risk by 80%" "Every single cell in my body is happy and healthy" "Reprogram your subconscious with positive affirmations" Chapters 00:00Introduction and Life Updates 02:20Weather, Rain, and Seasonal Changes 04:05Home Decor and Furniture Cleaning 05:44Washable Couches and Furniture Innovations 08:00Interior Design Help and Local Resources 10:20Japan's Centenarians and Longevity Factors 12:10Healthy Habits and Community Engagement 13:48Healthcare Challenges and Navigating Bills 16:03Preventative Measures for Ovarian Cancer 17:53The Power of Trapped Emotions and Emotional Release 21:24Podcast Success and Women in Media 23:56Mind Movies and Manifestation Techniques 30:36The Happy Little Cells Song and Affirmations 34:02Upcoming Travel and Personal Plans 35:21Final Thoughts and Why Nots

  Summary Join Jayla and Shaye as they chat about life, health, and personal growth, exploring topics like trapped emotions, healthy aging, and the power of positive affirmations. This episode offers practical insights and a light-hearted look at how to live a happier, healthier life.   Keywords:  personal growth, health, trapped emotions, positive affirmations, aging, wellness, mental health, lifestyle, self-care, motivation   Key Topics Trapped emotions and their impact on health Longevity secrets from Japan and their lifestyle habits Preventative health measures like fallopian tube removal The concept of mind movies for manifestation The role of community and social connections in aging well Sound Bites "Removing fallopian tubes can reduce ovarian cancer risk by 80%" "Every single cell in my body is happy and healthy" "Reprogram your subconscious with positive affirmations" Chapters 00:00Introduction and Life Updates 02:20Weather, Rain, and Seasonal Changes 04:05Home Decor and Furniture Cleaning 05:44Washable Couches and Furniture Innovations 08:00Interior Design Help and Local Resources 10:20Japan's Centenarians and Longevity Factors 12:10Healthy Habits and Community Engagement 13:48Healthcare Challenges and Navigating Bills 16:03Preventative Measures for Ovarian Cancer 17:53The Power of Trapped Emotions and Emotional Release 21:24Podcast Success and Women in Media 23:56Mind Movies and Manifestation Techniques 30:36The Happy Little Cells Song and Affirmations 34:02Upcoming Travel and Personal Plans 35:21Final Thoughts and Why Nots

Featuring perspectives from Dr Gottfried E Konecny and Dr Brian M Slomovitz, including the following topics: Introduction (0:00) Preventing Ovarian Cancer (1:04) Endometrial Cancer (5:27) Ovarian Cancer (25:36) Cervical Cancer (54:04) CME information and select publications

Lori Sill has been through cancer twice. When she reached her last treatment the second time, she couldn't ring the bell — she'd rung it once already, and it hadn't meant what everyone said it would mean. In this episode, Mechelle finally brings her best friend of more than a decade to the mic. Lori talks openly about what she's living right now: the recovery nobody prepares you for, the years it took last time to get her strength back, the mental gymnastics of every new ache, and why going through it a second time was harder because she already knew what was coming. She also shares what changed in round two, from how she handled the medications to the boundaries she's holding now around her work and her energy. Their friendship runs underneath all of it. They go back to the hike neither of them wanted to be on, the gas station drinks that became a lifeline, and the time on the couch when a quiz from a book pulled the blinders off Lori's marriage. Lori is also the reason this show exists — she went first into the oils, into Reiki, into the shamanic work, and left the door open behind her every time. Then they pull four Glow & Tell cards — Mind, Spirit, Body, and Soul. Lori answers what thought pattern she had to unlearn, how she explains the unseen to someone who only trusts proof, what her body does when it feels truly safe, and the difference between forgiveness and simply moving on. If you're in the after — the part where everyone thinks you're fine — this one's for you.Watch the video version in the wholeness library.Explore The Wholeness Library App FREE!Apple:https://apps.apple.com/us/app/wholeness-library/id1545002697 ⁠Android:https://play.google.com/store/apps/details?id=com.thewholenessnetwork.thewholenessnetworkOn the web https://www.thewholenessnetwork.com/⁠Follow us⁠https://www.instagram.com/thewholenessnetwork/⁠⁠https://www.facebook.com/thewholenessnetwork⁠Leave us a message! tel:646-883-3350Information is intended for entertainment only

Sue Weldon is the founder, CEO, and primary wellness advocate of Unite for Her, a national non-profit organization dedicated to supporting individuals diagnosed with breast and ovarian cancer through integrative care, education, and community resources. Under her leadership, the organization expanded into a national non-profit that has served thousands of breast and ovarian cancer patients across the U.S. The non-profit pairs traditional medical oncology with evidence-based integrative therapies, focusing heavily on underserved communities, equity, and whole-patient recovery. Weldon continues to speak nationally on patient advocacy, integrative wellness, and non-profit leadership. She is also the author of Heal Empower Restore, a book focused on integrative approaches and wellness strategies for cancer recovery. As a sexual health consultant for Unite for Her, one of our co-hosts, Sabitha Pillai-Friedman, continues to volunteer for the organization. She offers workshops, training programs and sex education classes to people affected by breast and ovarian cancers. If you want to catch up on other shows, just visit our website and please subscribe! We love our listeners and welcome your feedback, so if you love Our Better Half, please give us a 5-star rating and follow us on Facebook and Instagram. It really helps support our show! As always, thanks for listening!

Featuring perspectives from Dr Rachel N Grisham, including the following topics: Case: A woman in her early 40s with recurrent low-grade serous ovarian cancer (LGSOC) and prior treatment with a MEK inhibitor receives avutometinib/defactinib on the RAMP 301 trial (0:00) Case: A woman in her early 70s with recurrent KRAS-mutated LGSOC receives avutometinib/defactinib and develops muscle weakness (10:03) Case: A woman in her late 70s with KRAS-mutated recurrent LGSOC develops congestive heart failure on trametinib and then receives avutometinib/defactinib (16:15) Case: A woman in her mid 60s with recurrent BRAF V600E LGSOC has concerns about side effects and receives single-agent dabrafenib (19:49) CME information and select publications

Featuring perspectives from Dr Rachel N Grisham, including the following topics: Mechanism, clinical evidence and practical use of avutometinib with defactinib for recurrent low-grade serous ovarian cancer (LGSOC) (0:00) A Phase III trial of letrozole alone as front-line treatment for LGSOC (11:11) Current and future role of avutometinib with defactinib for LGSOC (19:23) A Phase II/III trial of trametinib for recurrent LGSOC: Biomarker analyses and clinical implications (21:37) CME information and select publications

Send us Fan MailEvening Prayer (Glory to God; Forgiving; Bible Translators; Ovarian Cancer; Lonely; Praying for You; Lord is with us) #Jesus #prayer #Christian Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peaceaimingforjesus.comYouTube Channel https://www.youtube.com/@aimingforjesus5346Instagram https://www.instagram.com/aiming_for_jesus/Threads https://www.threads.com/@aiming_for_jesusX https://x.com/AimingForJesusTik Tok https://www.tiktok.com/@aiming.for.jesus

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/FQR865. CME/MOC/CC/AAPA credit will be available until September 8, 2027.Powering Pathology Precision: Expert Strategies for Folate Receptor Alpha Testing to Guide Personalized ADC Care in Advanced Ovarian Cancer In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AbbVie.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/FQR865. CME/MOC/CC/AAPA credit will be available until September 8, 2027.Powering Pathology Precision: Expert Strategies for Folate Receptor Alpha Testing to Guide Personalized ADC Care in Advanced Ovarian Cancer In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AbbVie.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/FQR865. CME/MOC/CC/AAPA credit will be available until September 8, 2027.Powering Pathology Precision: Expert Strategies for Folate Receptor Alpha Testing to Guide Personalized ADC Care in Advanced Ovarian Cancer In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AbbVie.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/FQR865. CME/MOC/CC/AAPA credit will be available until September 8, 2027.Powering Pathology Precision: Expert Strategies for Folate Receptor Alpha Testing to Guide Personalized ADC Care in Advanced Ovarian Cancer In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AbbVie.Disclosure information is available at the beginning of the video presentation.

Do fertility medications increase the risk of breast cancer? Could IVF raise the chances of ovarian or uterine cancer later in life? And how can you separate scientific fertility research from fear-provoking headlines? In this episode of Brave & Curious, Dr. Lora Shahine examines why this fear exists and explores what decades of research actually reveal about fertility medications, IVF, and cancer risk. She explains why this topic is difficult to study, including the need to distinguish the effects of fertility treatment from underlying infertility diagnoses such as endometriosis, PCOS/PMOS, anovulation, and never having carried a pregnancy. Dr. Shahine also discusses the important nuance around prolonged Clomid use, the role of personal risk factors and routine cancer screening, and why patients deserve to make fertility treatment decisions based on evidence rather than fear. In this episode you'll hear: [1:32] A Common Question: Do fertility medications increase my risk of breast cancer? [2:27] Why Research Is Hard [4:44] Breast Cancer Evidence [5:50] Key Study Highlights [9:27] Clomid Cycle Nuance [10:05] Other Cancer Risks (Uterine Cancer, Ovarian Cancer) [12:46] Takeaways And Screening Dr. Shahine's Weekly Newsletter on Fertility News and Recommendations Follow @drlorashahine Instagram | YouTube | Tiktok | Her Books Join the Learn at Pinnacle app to earn FREE CE Credit for listening to this episode! This episode was produced by Audiotocracy Podcast Production.  

In this podcast episode, BJ Rimel, MD, and Elizabeth Lee, MD, discuss the scientific rationale for targeting CDH6 in ovarian cancer and the emerging role of CDH6-directed antibody–drug conjugates (ADCs) in platinum-resistant disease, including:CDH6 biology, expression patterns, and its potential as a therapeutic target in ovarian cancerEarly-phase efficacy data with investigational CDH6-directed ADCs, including raludotatug deruxtecan (R-DXd) and CUSP06, and an ongoing phase III trial of R-DXdSafety considerations with CDH6-directed ADCs, including cytopenias, gastrointestinal toxicities, fatigue, and interstitial lung disease/pneumonitisConsiderations for sequencing ADCs, including the potential impact of target expression, payload class, and mechanisms of resistancePresenters:BJ Rimel, MDDivision Chief, Gynecologic OncologyProfessor, Department of OB/GYNUniversity of WashingtonClinical Director of Gynecologic OncologyFred Hutchinson Cancer CenterSeattle, WashingtonElizabeth Lee, MDDivision of Gynecologic OncologyCenter for Cancer Therapeutic InnovationDepartment of Medical OncologyDana-Farber Cancer InstituteBoston, MassachusettsLink to full program: https://bit.ly/3SqCAZ6Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Drs. Jamie Lesnock and Sara Bouberhan join the podcast to discuss the first ASCO guideline on systemic treatment for recurrent ovarian cancer. They provide a comprehensive overview of the evidence-based recommendations for patients with both platinum-sensitive and platinum-resistant or platinum-refractory disease. The discussion covers systemic therapy options, the role of maintenance therapy with agents like bevacizumab, and the nuanced recommendations for secondary cytoreductive surgery based on mixed clinical trial results. Drs. Lesnock and Bouberhan emphasize the importance of an individualized, multidisciplinary approach to care. As this is a living guideline, they also look ahead to emerging evidence that will shape future updates. Read the full living guideline, "Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0," at www.ascopubs.org/guidelines/systemic-treatment-ovarian-cancer-recurrence" LINK TO FULL TRANSCRIPT

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/JMM865. CME/MOC/NCPD/AAPA credit will be available until August 16, 2027.Next-Generation Strategies in Advanced Ovarian Cancer: Are You Prepared to Harness Novel Mechanisms of Action and the Latest Therapeutic Innovations? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from Corcept Therapeutics, Inc. and Verastem Oncology.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/JMM865. CME/MOC/NCPD/AAPA credit will be available until August 16, 2027.Next-Generation Strategies in Advanced Ovarian Cancer: Are You Prepared to Harness Novel Mechanisms of Action and the Latest Therapeutic Innovations? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from Corcept Therapeutics, Inc. and Verastem Oncology.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/JMM865. CME/MOC/NCPD/AAPA credit will be available until August 16, 2027.Next-Generation Strategies in Advanced Ovarian Cancer: Are You Prepared to Harness Novel Mechanisms of Action and the Latest Therapeutic Innovations? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from Corcept Therapeutics, Inc. and Verastem Oncology.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/JMM865. CME/MOC/NCPD/AAPA credit will be available until August 16, 2027.Next-Generation Strategies in Advanced Ovarian Cancer: Are You Prepared to Harness Novel Mechanisms of Action and the Latest Therapeutic Innovations? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from Corcept Therapeutics, Inc. and Verastem Oncology.Disclosure information is available at the beginning of the video presentation.

Broadcast from KSQD, Santa Cruz on 8-20-2026: An emailer asks about amlexanox for mast cell activation syndrome (MCAS). Dr. Dawn first walks through MCAS diagnostic criteria—requiring symptoms across at least two of four categories (skin, low blood pressure, abdominal, respiratory), with serum tryptase testing performed both during and after a flare. She grades amlexanox as a C: originally FDA-approved only as a topical paste for canker sores, later approved in Japan as an asthma treatment, but never validated for MCAS and pushed largely by a single compounding pharmacy and its influencer clones. She recommends conventional agents first—antihistamines, montelukast, cromolyn, quercetin, aspirin for flushing, and Xolair anti-IgE antibodies for severe cases—plus microcrystalline cellulose as the safest capsule filler if compounding of amellanox is pursued. Most ovarian cancers—including nearly all fatal cases—actually originate in the fimbriae of the fallopian tubes rather than the ovaries themselves. Opportunistic salpingectomy tacks a five-minute fallopian tube removal onto any abdominal surgery (tubal ligation, hernia repair, gallbladder, appendectomy), potentially reducing lifetime ovarian cancer risk by 65% -80% based on epidemiological data from Swedish, Canadian, and Danish registry studies. Dr. Dawn recommends particular consideration for non-childbearing women with BRCA1/2 or family history of breast or ovarian cancer. Deep brain stimulator devices manufactured after 2020 (about 40,000 U.S. patients) contain adaptive-DBS capability that can be activated via firmware upgrade without additional surgery. Rather than delivering constant stimulation like older devices, adaptive DBS reads beta oscillations (13-30 Hz motor-control brainwaves) in the basal ganglia and modulates output in real time—reducing stimulation as L-DOPA peaks from drugs and increasing it as medication wears off, smoothing the swings between agitation and freezing. Sleep improvement has emerged as a notable secondary benefit, potentially slowing disease progression. The technology is also being investigated for dystonia, essential tremor, OCD, and Tourette's syndrome. Chinese company StarMed is developing brain-computer interfaces closely resembling Neuralink designs, benefiting from aggressive government funding, large patient populations, and reduced tort liability. One trial uses an eight-probe device placed atop the dura mater (avoiding brain penetration) connected to a pneumatic glove that has restored eating and drinking function in about twenty paralyzed patients over twenty months. A more invasive Shanghai trial implanted 256 probes on the neural cortex of a woman with epilepsy who could operate social media and control a wheelchair within two weeks; a related U.S. system using 65 hair-thin sensors enabled speech with just ten-millisecond delay. An emailer describes recurring two-week viral illnesses (sore throat, swollen glands, congestion, cough, body aches) recurring every 4-6 weeks. Dr. Dawn frames the question as either impaired immunity or changed exposure. She recommends starting with a CBC to rule out blood dyscrasias like leukemia, checking urine mycotoxins for mold exposure, then examining behavioral changes—new job, handling cash before eating, and the well-documented protective effect of masking in public that dramatically reduced cold rates during COVID. Dr. Dawn covers three health policy items. The good: new USDA dietary guidelines flip the food pyramid, putting protein, dairy, healthy fats, vegetables, and fruits at the top, with whole grains reduced to a small band, and it's recommendation 1.2 g/kg protein daily. The bad: an executive order attempting to reduce childhood vaccines from 18 to 11 and separate MMR into individual components—impossible since no U.S. manufacturer makes the individual antigens, and misguided since infant hepatitis B vaccination prevents mother-to-child liver cancer transmission. The ugly: a 26-year-old heart transplant recipient whose insurer initially dropped coverage of her generic anti-rejection drug, then "ghost approved" it at $1,000 for 90 days versus the previous $180. Mark Cuban's Cost Plus Pharmacy now supplies her the same medication for $300 (cost plus 15% profit plus 5% handling), highlighting the massive markups embedded in the standard pharmacy chain. For a time before that, the mother of the heart donor stepped up and paid for the recipients anti-rejection drugs to keep her son's heart beating.

Harper Wengrod was born on January 12th of 2024 and by the end of that year , a lump on her abdomen that her dad Joe found after Thanksgiving that was thought to be Neuroblastoma was the probable cause. That was not to be the case however as Joe and Melanie were to learn that Harper was actually suffering from Stage 3 Sertoli Cell Ovarian Cancer. This is such a rare diagnosis for a child not even a year old to receive, as Ovarian Cancer is found in women decades older than that. Harper continues to fight her battle on a daily basis and physically it looks as if she is a completely healthy toddler.

What if one of medicine's deadliest cancers has been hiding in plain sight? New York Times science writer Gina Kolata explains the discovery that's changing how doctors prevent ovarian cancer.

Dr. Denise Schumacher from IMA Healthcare takes a look into a recent New York Times article about ovarian cancer and how it can start outside the ovaries and not present for a lengthy amount of time. Dr. Schumacher has some amazing insight and details how this knowledge isn't new, but physicians are approaching the way we chose preventative care in a new way.See omnystudio.com/listener for privacy information.

One of the deadliest forms of cancer for women may not start where we once believed. Researchers now know nearly all fatal ovarian cancers begin in the fallopian tubes, not the ovaries. Stephanie Sy discusses with Dr. Rebecca Stone, a professor in the Johns Hopkins Department of Gynecology and Obstetrics, how this understanding is important for patient care. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

In May 2022, Tina Calderone-Roth felt terrible. She was experiencing fatigue, shortness of breath and nausea.  She also gained close to 15 pounds in three days.  Nurses she knew suggested she go to the emergency department.  Two paracentesis procedures resulted in the removal of 6.5 liters of fluid.  Doctors initially noticed a large abdominal mass, but further tests indicated ovarian masses of 7cm and 10cm.  Tests also showed Tina had the BRCA-2 gene mutation.  She opted to, all at once, undergo a hysterectomy and bilateral oophorectomy.  A week after the procedure, it was learned there had been Stage 1B cancer in both ovaries.  Tina was next put on six rounds of chemotherapy with carbo-taxol, avastin and the PARP inhibitor, lynparaza.  Because of the BRCA-2 gene mutation and with it, the possibility of breast, she decided to get a bilateral mastectomy.  Tina reached survivorship and these days, while she can no longer run, she can jog and power walk.    Tina had been working for more than two decades in the care management sector of health care in 2022, when her health took a sudden turn for the worse.  She was feeling unusually tired, had shortness of breath and her weight shot up by 15 pounds in three days.  She had no idea what was going on, but consulted friends who were nurses, and they suggested she go to the emergency department, which she did in the middle of a workday.   Tina underwent a CT scan, ultrasound, electrocardiogram, blood work and genetic testing.  A subsequent pair of paracentesis procedure removed a combined 6.5 liters of fluid, which explained her sudden, sharp weight gain.  Those tests also showed she had a large abdominal mass. Further tests were conducted and they revealed two large ovarian masses, measuring roughly 7cm and 10cm.  Meanwhile, the genetic testing revealed Tina had the BRCA-2 gene mutation.  She did not want to have multiple surgeries, so she elected to have a hysterectomy along with the removal of both ovaries.  About a week later, it was determined the ovaries were cancerous.   She and her care team settled on a six-round chemotherapy regimen of carbo-taxol, avastin and the PARP inhibitor, lynparaza.  Like many dealing with chemotherapy, Tina was fatigued, had nausea and suffered hair loss, but got through it.  She was still concerned about the possibility of being diagnosed with breast cancer because of the gene mutation, so she decided to undergo a bilateral mastectomy.   If Tina Calderone-Roth's health before her diagnosis could be considered 100 percent, these days she considers her health to be at 90 percent.  While she can no longer run, Tina says she can jog and power walk.   Additional Resources:   Tina's Book:   "Where Fears Meets Faith," available on amazon.com and barnesandnoble.com, in paperback and Kindle          

Most women know the warning signs of breast cancer. Far fewer know what ovarian cancer can actually look like—and that's a problem. In this episode, Danielle shares the seven early signs of ovarian cancer every woman should know, why they're so often mistaken for everyday health issues, and how to recognize when a symptom deserves more than a quick explanation or reassurance. She also discusses why ovarian cancer is notoriously difficult to detect early, what a proper medical evaluation may include, and why paying attention to changes in your body matters. This episode isn't about creating fear—it's about creating awareness. You'll also learn how to advocate for yourself, what questions to ask if your symptoms aren't improving, and how to have productive conversations with your healthcare provider. Because when it comes to your health, trusting your instincts and seeking answers can make all the difference.   Disclaimer: This podcast is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. Listening does not establish a patient-provider relationship with Danielle Kepics, PA-C, or any of her businesses. Always consult your qualified healthcare provider before making changes to your medications, supplements, diet, exercise, or treatment plan. Never disregard or delay medical care based on information shared in this podcast.   Learn more about working with Danielle  Shop Danielle's masterclasses (learn more in 60-90 minutes than years of dr appointments) Follow Danielle on IG Follow Empowered Mind + Body on IG  

Featuring perspectives from Dr Bradley J Monk, Dr David M O'Malley, Ms Kathryn M Schlenker and Ms Jaclyn Shaver, moderated by Dr O'Malley, including the following topics: Introduction (00:00) Overview of Ovarian Cancer (OC) (2:12) Role of PARP Inhibitors in Advanced OC (4:56) Current and Potential Future Role of Mirvetuximab Soravtansine in OC (28:45) Role of Relacorilant in Advanced OC (57:08) Utility of Immune Checkpoint Inhibition in Advanced OC (1:14:12) NCPD information and select publications

This Day in Legal History: Congress Shrinks the Supreme CourtOn July 23, 1866, Congress passed the Judicial Circuits Act, and in doing so did something that sounds almost unimaginable today: it shrank the Supreme Court. The Act provided that the Court would gradually contract from ten justices down to seven, as sitting justices died or retired and their seats simply went unfilled. Yesterday we talked about Franklin Roosevelt's failed attempt to enlarge the Court to overpower it; today's anniversary is the mirror image—Congress reducing the Court's size for pointedly political reasons.The politics were about President Andrew Johnson. Johnson, who had ascended to the presidency after Lincoln's assassination, was locked in a bitter struggle with the Radical Republicans in Congress over Reconstruction. Congress did not trust him, and one thing it was determined to deny him was the power to shape the Supreme Court. By legislating that upcoming vacancies would go unfilled until the Court shrank to seven, Congress effectively stripped Johnson of any Supreme Court appointments. It was court-unpacking as a weapon of inter-branch warfare—using Congress's control over the Court's size not to change its rulings directly, but to lock a distrusted president out of influencing it.The size of the Supreme Court has never been fixed by the Constitution—it's set by statute, and it has ranged from six at the founding up to ten and back down over the country's first century. After Johnson left office, Congress promptly passed the Judiciary Act of 1869 and settled the number at nine, where it has remained ever since. The significance of July 23, 1866 is that it's the clearest historical example of Congress manipulating the Court's very size for immediate political advantage—and, paired with the 1937 court-packing fight, it bookends the story of how the number nine came to feel sacrosanct even though it never actually was. The Court's independence, it turns out, has always rested partly on a political truce about not touching its structure.A Manhattan federal judge is set to weigh today whether to throw out the Justice Department's subpoenas to New York Times journalists who reported on security concerns about President Trump flying on a Qatari-donated Air Force One. This is the next chapter of a story we covered when the subpoenas first landed: they were issued July 10 by the Manhattan U.S. Attorney, and U.S. District Judge Arun Subramanian has paused their enforcement pending this afternoon's hearing. The two sides want very different things. Prosecutors have asked the judge merely to put the subpoenas on hold for a couple of weeks, saying the investigation's next steps could shape his decision; the Times wants them quashed outright, arguing they're designed to harass and intimidate journalists in violation of the First Amendment. The legal backdrop is genuinely unsettled. There is no absolute reporter's privilege under federal law—prosecutors correctly note the First Amendment doesn't categorically excuse reporters from testifying in criminal investigations—but courts have long been wary of subpoenas that function as fishing expeditions to unmask sources. The significance is that this hearing is a concrete test of where that line falls, and it lands amid a broader pattern we've tracked all month of friction between the administration and the press. However Judge Subramanian rules, it will be an early data point on how much protection newsgathering gets when the government wants to know who talked.US judge to weigh New York Times subpoenas over Trump plane reporting | ReutersThe teenager at the center of a closely watched lawsuit blaming social media for his depression and anxiety has dropped his claims against Meta just days before trial. The plaintiff, a 15-year-old known in court papers as R.K.C., had originally sued four companies—Google's YouTube, Meta's Instagram, Snap's Snapchat, and ByteDance's TikTok—alleging their platforms were engineered to be addictive and harmed his mental health. YouTube, TikTok, and Snap all reached confidential settlements earlier, which would have left Meta as the lone defendant when the case went before a Los Angeles jury on July 27. Instead, R.K.C. withdrew, ending the case. Here's why this matters beyond one teenager. His was a “bellwether” case—one of a small set of representative lawsuits chosen from a huge pool of similar claims and tried first, so both sides can see how juries react and use those signals to gauge settlement values across the whole litigation. When a marquee bellwether evaporates right before trial, it sends a message, though an ambiguous one: it could reflect a quiet settlement, a weakness in this particular plaintiff's proof, or simply strategic repositioning. The significance is that the sprawling social-media-harm litigation against these platforms rolls on, but this particular test balloon won't be inflated—depriving both the companies and the thousands of other plaintiffs of a data point they were watching closely.Teen plaintiff suing Meta over mental health harms drops his claims against company days before trial | ReutersA federal judge has cast serious doubt on roughly 69,000 lawsuits claiming that Johnson & Johnson's talc products caused ovarian cancer, warning the plaintiffs they must come forward with better evidence or risk having their cases dismissed. U.S. Magistrate Judge Rukhsanah Singh in Trenton, New Jersey, zeroed in on a problem at the heart of the litigation: causation. In a mass tort like this, plaintiffs generally have to show not just that a product can cause harm in the abstract—”general causation”—but that it caused this particular plaintiff's disease—”specific causation.” Judge Singh noted that two of the plaintiffs' own expert witnesses, testifying in preparation for a set of bellwether trials, conceded they could not rule out other possible causes of the women's cancers. That's a serious admission, because it goes to whether the experts can offer an opinion that's admissible at all under the rules that make judges the “gatekeepers” of scientific testimony. If you've been listening, this should ring a bell—it's the same expert-gatekeeping battleground we saw in the Tylenol-autism case, just cutting the other direction. Here the judge ordered plaintiffs to explain, by November 19, why their cases shouldn't be tossed for lack of an admissible expert opinion tying J&J's talc to their specific cancers. The significance is that after years of litigation, settlements, and failed bankruptcy maneuvers, the whole edifice of these 69,000 claims may hinge on a question of scientific proof—and the judge just signaled the plaintiffs have a real problem.US judge casts doubt on 69,000 cases alleging J&J talc caused cancer | ReutersAnd finally, in a piece I wrote for Forbes this week, I make an argument that runs underneath a lot of the tax stories we've covered lately: the tax code is only as real as its enforcement. My core claim is that defunding the IRS doesn't actually shrink the tax code—it quietly splits it into two.Here's the framing I start with. Washington has a strange way of talking about tax enforcement. Money to help the IRS collect taxes that are already legally owed gets described as spending, waste, or bureaucratic excess—but when Congress cuts that funding and less revenue comes in, the shortfall gets treated like weather, as if it just happened. I think that's exactly backwards. Congress can write whatever rates, deductions, partnership rules, and anti-abuse provisions it likes, but without skilled auditors and functioning technology, a big chunk of those rules becomes purely aspirational.And crucially, that aspiration isn't evenly distributed. For most wage earners, there's almost no room to maneuver: your income is reported by your employer, your taxes are withheld before you ever see the paycheck, and a computer can flag a mismatch without a human ever looking at your return. But wealthier filers and large businesses often operate through partnerships, closely held entities, cross-border transactions, and complex securities arrangements that take specialized expertise and real time to unwind. So my point is that defunding the IRS doesn't create a smaller tax code—it creates two codes: a statutory, basically inescapable one for people whose income is visible, and a negotiated one for people whose finances are complicated enough to delay, obscure, or contest what they owe. Strip out the enforcement capacity, and the nominal rule stays on the books while its practical effect on the highest earners quietly weakens. That's regressive—a backdoor tax cut for the taxpayers best positioned to resist enforcement.There's a new bill, the Stop CHEATERS Act, that would restore enforcement funding, and I think its sponsors are right about the underlying problem. But I argue they should retire the “fair share” language they've wrapped around it. “Fair share” is subjective—reasonable people can argue forever about whether capital gains should get preferential treatment or whether the top rate is too high or too low, and those are legitimate legislative questions. But that's not the issue here. Congress already wrote the laws; taxpayers are already obligated to follow them. The case for funding the IRS isn't about inventing a new standard of fairness after the fact—it's about consistently administering the standards we already have. By leaning on “fair share,” Democrats risk making basic enforcement sound like a partisan redistribution project when the stronger, harder-to-dismiss argument is simply this: if Congress imposes a tax, the government should be funded well enough to collect it. Anything less isn't restraint or a considered policy choice—it's a quiet exemption for those who can afford to fight.The Tax Code Is Only As Real As Its Enforcement | Forbes This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Featuring perspectives from Dr Ramez N Eskander, Dr Ursula Matulonis, Dr Kathleen N Moore, Dr Alexander B Olawaiye and Dr David M O'Malley, moderated by Dr Moore, including the following topics: Introduction (00:00) Current Role of PARP Inhibitors in the Management of Advanced Ovarian Cancer (OC) — Prof Eskander (2:40) Strategies Targeting Folate Receptor Alpha in Advanced OC — Dr Matulonis (27:41) Other Approved and Promising Investigational Antibody-Drug Conjugates for Advanced OC — Dr Moore (52:12) Other Novel Agents and Strategies for Advanced OC — Dr O'Malley (1:14:35) Diagnosis and Management of Adverse Events Associated with Common Therapies for Advanced OC — Dr Olawaiye (1:39:39) CME information and select publications

Could recognizing the symptoms sooner change the course of a cancer journey?In this heartfelt episode of Metabolic Matters, host Christina Mason sits down with Trish Kifer, a stage IIIC ovarian cancer survivor and author, and her husband Roger Kifer, for an inspiring conversation about hope, partnership, faith, and whole-person healing.Trish and Roger vulnerably share Trish's remarkable journey: from subtle symptoms, including painful intercourse, abdominal pain, incontinence, and feeling full quickly, that were initially attributed to early menopause, to a stage IIIC ovarian cancer diagnosis. Their healing journey extended far beyond conventional treatment and the wisdom they share is priceless. Together, they discuss the importance of listening to your body, building the right healthcare team, and becoming an active participant in your own healing. As Trish searched for ways to better support her health, she began exploring nutrition, metabolic health, reducing environmental toxins, therapeutic fasting, stress management, sauna use and other lifestyle strategies alongside her medical care.Trish and Roger also offer an important perspective on navigating cancer as a couple. They reflect on how cancer strengthened their marriage, deepened their faith, and taught them to approach each day with gratitude, purpose, and intention. Roger also shares the often-overlooked experience of the caregiver and the importance of finding support throughout the journey.More than a story about surviving cancer, this powerful conversation reminds us to trust our intuition, seek answers when something doesn't feel right, and never underestimate the impact of hope, community, and love.As Trish says, if sharing her story helps even one person seek care sooner, then every step of the journey has been worth it.Connect with our Guests:Website: https://hopejourney.life Instagram: https://www.instagram.com/kifertrish/ Facebook: https://www.facebook.com/trish.kifer LinkedIn: https://www.linkedin.com/in/trish-kifer-20818a116/ Learn More About the Program Trish took to support her knowledge of metabolic health and healing!www.metabolicregen.comAbout Your Host: Christina Mason is a lifelong storyteller, educator, and truth-seeker whose journey—from music and teaching to entrepreneurship—has always been guided by curiosity. Following her own breast cancer diagnosis, she turned her focus toward metabolic health and healing. As host of Metabolic Matters, she creates space for real people to share real stories and the many paths that shape how we understand health.Follow the Show: Website: www.metabolicmatters.comInstagram: https://www.instagram.com/metabolicmatters_/ Facebook: https://www.facebook.com/profile.php?id=61577488944537 Tiktok: https://www.tiktok.com/@metabolicmatters LinkedIn: https://www.linkedin.com/company/metabolic-matters Youtube: https://www.youtube.com/@MetabolicRegen © 2026 Metabolic Regen. All rights reserved. Produced by Metabolic Regen. Hosted on Acast. See acast.com/privacy for more information.

Scott and Crew talk about Chris Evert, Don Mattingly, Jack Drury, Buffalo Sabres, Deter Jeter, Curtis Granderson, Carlos Mendoza, and More. #tennis #chrisevert #wimbledon #ovariancancer #everttennisacademy #bocaraton #florida #philadelphiaphillies #donmattingly #jackdrury #nashvillepredators #frankjselketrophy #backmalenstyn #buffalosabres #cleonjones #carlosbeltron #darrylstrawberry #davidwright #franciscolindor #edgardoalfonzo #keithhernandez #tomseaver #johnfranco #mikepiazza #petealonzo #daveyjohnson #ussnewyork #twintowers #derekjeter #tonyfernandez #tombrady #drewbledsoe #curtisgranderson #jorjaposada #teamitaly #worldbaseballclassic #carlosmendoza #barrackobama #newyorkcity #miguelrojas #earthquake #venezuela #family #towsonstate #baltimore #stansaunders #keywest #rollerderby #florida #hockeynightincanada #clubhouse #davedombrowski #davedoerer #barrytrotz #necher #ronaldkoerer #lindyruff #cbc #canadadry #rollerhockey #martinanavratilova #cancer #chemotherapy #berlinwall #eiffletower #ronswaboda #garycarter #bobbybonilladay #dwightgooden #jacobdegrom #gilhodges #nolanryan #stevecohen #howardjohnson #steel #lougehrig #wallypopp #anthonybolpe #billbelichick #brettfavre #donmakowski #kareemabduljabbar #magicjohnson #torihunter #bradausmus #catcher #albertpujols #subscribe #video #viral #podcast

How Targeted Therapies Are Reshaping Treatment for Platinum-Resistant Ovarian Cancer Platinum-resistant ovarian cancer remains one of the most challenging settings in oncology, with limited treatment options and historically poor outcomes for many patients. On this episode of Unscripted, the AMCP Podcast, guest host Abby Kim, PharmD, BCOP, Senior Director of Clinical Strategy and Oncology Specialty Solutions at Prime Therapeutics, sits down with Kathleen Moore, MD, Deputy Director of the Fred & Pamela Buffett Cancer Center and Professor of Obstetrics and Gynecology at Nebraska Medicine, to discuss the evolving treatment landscape for recurrent ovarian cancer and the growing role of biomarker-driven care. Dr. Moore explores the history and challenges of treating platinum-resistant disease, reviews the clinical evidence behind ELAHERE®, examines the importance of folate receptor alpha testing, and shares insights on treatment sequencing, patient-reported outcomes, safety and tolerability considerations, and emerging therapies that may further expand options for patients and inform decision-making across managed care. Sponsored by Abbvie, Inc. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

In today's episode, we spoke with David O'Malley, MD. Dr O'Malley is a professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–James in Columbus, Ohio. In our exclusive interview, Dr O'Malley discussed his approach to treatment selection and sequencing in platinum-resistant ovarian cancer, a disease setting he described as representing the highest unmet need in the field. He emphasized the central role of clinical trial enrollment and biomarker-driven decision-making, alongside practical patient-centered considerations, such as infusion schedule and quality of life.He highlighted the growing importance of antibody-drug conjugates (ADCs) in this setting, noting that folate receptor alpha and HER2 are the two biomarkers most relevant to current practice. Dr O'Malley outlined how National Comprehensive Cancer Network guidelines support treatment across a broader range of expression levels than initial approvals reflected, citing emerging data suggesting activity even at lower expression thresholds. He also addressed payload sequencing, explaining that outside of a clinical trial, he currently uses topoisomerase I–based ADCs and antimicrotubule-based ADCs each one time only, and remains open to targeting the same antigen again if the payload differs.The discussion also touched on combination strategies, resistance biology, and the evolving role of immunotherapy following the survival benefit observed with pembrolizumab (Keytruda) in the phase 3 KEYNOTE-B96 trial (NCT05116189). Dr O'Malley expressed enthusiasm for next-generation payloads, dual-target approaches, and the potential for bispecific antibodies and novel DNA damage response–targeting agents to define the post-ADC treatment landscape.Finally, Dr O'Malley underscored the need for more tumor biopsies to better characterize resistance mechanisms and called for expanded pharmaceutical investment in retreatment and cross-resistance studies to guide future sequencing decisions.

TODAY ON THE ROBERT SCOTT BELL SHOW: Live from the Beljanski Integrative Cancer Conference, Supreme Court Bayer Ruling, John Richardson, Laetrile/B17, Canadian Vaccine Injury Program, Embryo DNA Editing, Chris Evert Ovarian Cancer, Disparate Cancer Burden, and MORE! https://robertscottbell.com/live-from-the-beljanski-integrative-cancer-conference-supreme-court-bayer-ruling-john-richardson-canadian-vaccine-injury-program-embryo-dna-editing-chris-evert-ovarian-cancer-again-disparate-can/ Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

In this episode, we review the high-yield topic of ⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Ovarian Cancer⁠⁠⁠⁠⁠⁠ from the Oncology section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

Featuring perspectives from Dr Deborah K Armstrong and Dr David M O'Malley, including the following topics: Introduction (0:00) PARP Inhibitors and Strategies Targeting Folate Receptor Alpha in Advanced Ovarian Cancer — Dr Armstrong (4:37) Other Novel Agents and Strategies for the Treatment of Advanced Ovarian Cancer — Dr O'Malley (35:18) CME information and select publications

In this episode, we hear about a breakthrough drug called mirvetuximab, which has been dubbed a "biological missile" in the treatment of ovarian cancer. Plus, astronomers suggest some black holes may have formed before the stars in their host galaxies; a 'killer fungus' that could help habitats damaged by invasive moss; and Blue Origin officials assess the damage caused by the New Glenn rocket's dramatic explosion in Florida. Like this podcast? Please help us by supporting the Naked Scientists

Survivors who say they were abused by former Harrods owner Mohamed Al Fayed met Sir Keir Starmer yesterday afternoon, in what campaigners have described as a potentially significant moment. More than 400 allegations of sexual misconduct against Al Fayed, dating back to 1977, have now been made. The meeting was organised by The Survivors Trust and the All-Party Parliamentary Group on the Survivors of Mohamed Al Fayed and Harrods. Kylie Pentelow was joined by Lucy Duckworth from The Survivors Trust and survivor Carrie Lazell.A breakthrough drug for ovarian cancer that is kinder on the body and extends lives is now available on the NHS. Victoria Clare from Ovacome and patient Patricia Hill talk to Kylie. New Ground is the UK's first purpose-built co-housing community for women over 50, designed and developed on their own terms. Each resident has her own self-contained flat, along with shared spaces. The women moved in 10 years ago, and the community is still going strong. But what's it really like to live this way? And could co-housing be a model more women should consider? Kylie speaks to two residents, Jude and Ann.Stories about queens and princesses have shaped some of our most enduring ideas about womanhood. Historian Kate Williams joins Kylie to discuss her new book, Regina: A New History of Women and Power, which spans thousands of years, from the queens of ancient Egypt to the modern day.Presenter: Kylie Pentelow Producer: Corinna Jones

Dr. Marty Makary out as FDA Commissioner—was he the victim of a BigPharma purge? Are “liquid biopsies” useful for predicting recurrences, as well as guiding therapy, for cancer? Nighttime smartphone by adolescents surges, eroding kids' sleep needs; Persistent itch may require an “all of the above” approach to break its vicious cycle—could topical vitamin B12 provide an answer? Study critiques research methods that fast-tracked new Alzheimer's drugs.